Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etesevimab

- PMLiVE

EMA and FDA calls for innovative approaches for Gaucher disease medicines

The regulatory agencies also urge a similar method for all paediatric diseases

National Institute for Health and Care Excellence NICE logo

NICE backs Lilly’s rheumatoid arthritis drug Olumiant

The drug will be used alongside methotrexate to treat adults with severe, active RA

- PMLiVE

Europe delays EMA relocation decision

Will resolve the issue in November, one month later than expected

- PMLiVE

Shoring up the framework

European regulators add a measure of clarity to pharma’s uncertainty around Brexit

- PMLiVE

Samsung Bioepis wins CHMP nod for second Humira biosimilar

In addition to Imraldi the regulatory advisors also backed new medicines from AbbVie and Gilead

- PMLiVE

Merck gets CHMP backing for long-delayed oral MS drug

Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010

- PMLiVE

Lilly and NRAS launch arthritis awareness film campaign

Pharma firm's ‘Behind The Smile’ initiative coincides with RA awareness week

- PMLiVE

Woodford investment pushes Dementia Discovery Fund to £100m

Fund aims to back 40 projects over its 15-year term

Eli Lilly HQ

FDA fast-tracks Pfizer and Lilly’s tanezumab

The novel pain drug treats osteoarthritis and chronic low back pain

- PMLiVE

European regulators mull use of… QR codes

EMA’s Heads of Medicines Agencies committee outlines packaging proposals

Eli Lilly HQ

Lilly adds to data backing breast cancer candidate abemaciclib

US pharma giant’s drug achieves PFS rate of 16.4 months

- PMLiVE

Lilly pitches Cyramza at bladder cancer

Pharma firm is now armed with phase III data from its RANGE study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links